The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Clinical trial NCT00392171 · COMPLETED
Trial details
- NCT number
- NCT00392171
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-06-09
- Primary completion
- 2009-09-15
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.